Mizuho raised the firm’s price target on Edwards Lifesciences (EW) to $87 from $85 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $81 from $75 at Morgan Stanley
- Cautious Outlook for Edwards Lifesciences Amidst TAVR Sales Challenges and Market Share Concerns
- Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer
- Edwards Lifesciences initiated with a Buy at Argus